Format

Send to

Choose Destination
Wien Med Wochenschr. 2018 Nov;168(15-16):415-422. doi: 10.1007/s10354-017-0589-8. Epub 2017 Aug 21.

[Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].

[Article in German]

Author information

1
Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm, Ulm, Deutschland. barbara.bohn@uni-ulm.de.
2
Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Deutschland. barbara.bohn@uni-ulm.de.
3
Institut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland.
4
Forum Diabetologie, Surheim, Deutschland.
5
Gemeinschaftspraxis Kaltheuner - v. Boxberg, Leverkusen, Deutschland.
6
Ambulanz für Diabetologie und Ernährungsmedizin, Knappschaftskrankenhaus, Bottrop, Deutschland.
7
Patienten Praxis Berlin Tempelhof, Berlin, Deutschland.
8
Diabeteszentrum, Bad Aibling, Deutschland.
9
Diabetologische Schwerpunktpraxis, Jena, Deutschland.
10
Diabetologische Schwerpunktpraxis, Rosenheim, Deutschland.
11
Institut für Diabetesforschung, Helmholtz Zentrum München, München, Deutschland.
12
Diabeteszentrum Ludwigsburg, Ludwigsburg, Deutschland.
13
Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm, Ulm, Deutschland.
14
Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Deutschland.
15
Kinder- und Jugendkrankenhaus "AUF DER BULT", Hannover, Deutschland.

Abstract

BACKGROUND:

Glargine U300 (Gla-300) is a further development of glargine U100 (Gla-100). Since 2015, Gla-300 has been available in Germany and Austria. We compared patients initiating therapy with Gla-300 with patients starting with Gla-100. Moreover, it was investigated whether patients from real-life diabetes care differ from patients participating in the EDITION clinical study program.

METHODS:

Data are based on the diabetes registries DPV and DIVE. Patients started/switched to Gla-100 or Gla-300 in 2015 were included. Linear regression was applied for bodyweight (BW), BMI, HbA1C, daily total and basal insulin dose/kgBW and negative binomial regression for severe hypoglycemia. Data were adjusted for age, sex, and diabetes duration.

RESULTS:

14,123 patients were identified (Gla-100: 11,397; Gla-300: 2726). Gla-300 patients with T1D were older, T2D patients younger compared to subjects using Gla-100 (both p < 0.0001). In Gla-300 subjects, diabetes duration was longer (both p < 0.0001). Patients started/switched to Gla-300 had a higher BW, a higher BMI and a lower baseline HbA1C. The rate of severe hypoglycemia was comparable. Total and basal insulin doses/kgBW were higher in patients with Gla-300. DPV/DIVE subjects were older, had a lower BW, and were more frequently male compared to EDITION patients. HbA1C was higher in T1D patients from DPV/DIVE.

CONCLUSION:

Data from the diabetes registries DPV/DIVE indicate differences between Gla-300 and Gla-100 patients at the onset of insulin therapy. This analysis provides additional information to the EDITION clinical study program.

KEYWORDS:

Diabetes Registries; Glargine U300; Routine Care; Type 1 Diabetes; Type 2 Diabetes

PMID:
28828553
DOI:
10.1007/s10354-017-0589-8

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center